A $14.7M seed round has been raised by Cirrus Therapeutics, a University of Bristol spin-out developing treatments for blindness-causing eye diseases. The round was backed by Cedars-Sinai Intellectual Property Co., ClavystBio, Polaris Partners, and SEEDS (SG Growth Capital).
The company is focused on ocular immunology, with a lead program targeting dry age-related macular degeneration (AMD), the leading cause of vision loss in older adults. Cirrus’ approach centers on increasing the protein IRAK-M in retinal cells, a discovery made by co-founders Dr. Kai Chan and Dr. Andrew Dick that aims to address multiple disease pathways-a contrast to current AMD treatments, which target only one. The AMD market is projected to hit $27.5 billion by 2031.














